Vohamine

Vohamine, also known by its chemical name 2,6-diisopropylphenoxazine, is a synthetic compound that has been studied for its potential pharmacological properties. It was first synthesized in the 1950s and has since been investigated for its effects on the central nervous system.

The compound is structurally related to other phenoxazine derivatives, which have been explored for their potential as antipsychotic, antidepressant, and anxiolytic agents. Vohamine's mechanism of action is not fully understood, but it is believed to interact with serotonin receptors in the brain, which may contribute to its potential therapeutic effects.

Research on vohamine has been limited, and its use in clinical settings has not been widely established. Some studies have suggested that it may have sedative and anxiolytic properties, but these findings have not been consistently replicated. Additionally, the compound has been reported to have a low therapeutic index, meaning that the difference between an effective dose and a toxic dose is small, which limits its potential for safe and effective use.

Due to the limited research and the potential for adverse effects, vohamine is not currently approved for medical use in most countries. Further studies are needed to fully understand its pharmacological properties and potential therapeutic applications. As with any synthetic compound, it is important to approach vohamine with caution and under the supervision of a qualified healthcare professional.